In conclusion, the aggregated HRs for OS and PFS summarized in our systematic analyses revealed that in the comparison of anti-PD-1/PD-L1 agents with other control therapy, the PD-L1 expression was not an appropriate factor to predict the benefit of OS in epithelial carcinoma patients, but could be predictive for PFS. This evidence concerns the gene CD274 and carcinoma.